drugset
Drugs / Recombinant LH
last change Sep 2026 re-read 9 days ago

Recombinant LH

also known as Luveris · rLH

Protein / enzyme biologic

Developed for
infertility disorder · ovarian disorder
Investigated by
Assuta Hospital Systems · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · IVI Madrid · Maccabi Healthcare Services, Israel · University of Colorado, Denver

Trials 3

today NCT01500863 · Ph 4 NCT01457703 · not/applicable NCT01936077 · Ph 4
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 42 trials
Phase 4 NCT01500863 Nov 2011 → May 2012 ovarian hyperstimulation syndrome IVI Madrid Completed No outcome recorded
Phase 4 NCT01936077 Jun 2010 → May 2013 infertility disorder Assuta Hospital Systems Completed No outcome recorded
Phase not applicable1 trial
— NCT01457703 Jun 2010 → Jul 2013 obesity disorder University of Colorado, Denver Completed No outcome recorded
Comparator or background therapy3 trials
Phase 2 NCT06883890 Comparator Mar → Nov 2025 overdue ovarian disorder University Hospital of Modena Not yet recruiting No outcome recorded
Phase 4 NCT07121751 Comparator Sep 2025 → Aug 2026 overdue infertility disorder Dunamenti REK Istenhegyi IVF Center Not yet recruiting No outcome recorded
— NCT02244866 Comparator Oct 2012 → Apr 2014 infertility disorder Vietnam National University Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as recombinant LH “150 IU of recombinant FSH and 75 IU of recombinant LH (Pergoveris) daily subcutaneous injection” NCT02244866 ↗
5

NCT06883890 ↗

NCT07121751 ↗

NCT01500863 ↗

NCT01457703 ↗

NCT01936077 ↗
Known as Luveris “Drug: Recombinant LH (Luveris)” NCT06883890 ↗
Known as rLH “In the treatment group patients will receive the pretreatment with rLH, a daily dose of 187.5 IU (75 U in the morning and 112.5U in the evening) rLH treatment for 60 days will...” NCT06883890 ↗
Action Activate “Used to stimulate ovarian function in women.” NCT01457703 ↗
Modality Protein / enzyme biologic “recombinant luteinizing hormone” PMID 25740882 ↗ Mar 2015
Route Subcutaneous “150 IU of recombinant FSH and 75 IU of recombinant LH (Pergoveris) daily subcutaneous injection” NCT02244866 ↗